Your browser doesn't support javascript.
loading
Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical Immunotherapies.
Park, Jung-Hyun; Lee, Seung-Woo; Choi, Donghoon; Lee, Changhyung; Sung, Young Chul.
Afiliação
  • Park JH; Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Lee SW; Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea.
  • Choi D; Research Institute of NeoImmune Tech., Co, Ltd., Bio Open Innovation Center, Pohang 37666, Korea.
  • Lee C; Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea.
  • Sung YC; Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea.
Immune Netw ; 24(1): e9, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38455462
ABSTRACT
The cytokine IL-7 plays critical and nonredundant roles in T cell immunity so that the abundance and availability of IL-7 act as key regulatory mechanisms in T cell immunity. Importantly, IL-7 is not produced by T cells themselves but primarily by non-lymphoid lineage stromal cells and epithelial cells that are limited in their numbers. Thus, T cells depend on cell extrinsic IL-7, and the amount of in vivo IL-7 is considered a major factor in maximizing and maintaining the number of T cells in peripheral tissues. Moreover, IL-7 provides metabolic cues and promotes the survival of both naïve and memory T cells. Thus, IL-7 is also essential for the functional fitness of T cells. In this regard, there has been an extensive effort trying to increase the protein abundance of IL-7 in vivo, with the aim to augment T cell immunity and harness T cell functions in anti-tumor responses. Such approaches started under experimental animal models, but they recently culminated into clinical studies, with striking effects in re-establishing T cell immunity in immunocompromised patients, as well as boosting anti-tumor effects. Depending on the design, glycosylation, and the structure of recombinantly engineered IL-7 proteins and their mimetics, recombinant IL-7 molecules have shown dramatic differences in their stability, efficacy, cellular effects, and overall immune functions. The current review is aimed to summarize the past and present efforts in the field that led to clinical trials, and to highlight the therapeutical significance of IL-7 biology as a master regulator of T cell immunity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Immune Netw Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Immune Netw Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos